All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2023-07-03.
From the record
Adaptive Biotechnologies Corporation's filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2023-07-03) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+28% a year over 9 filed years; profitable in 0 of 9.
From the record
Adaptive Biotechnologies Corporation's 9 filed years say what it did: revenue went from $38 million in fiscal 2017 to $277 million in fiscal 2025, up 28% a year; it rose in 7 of 8 years; the deepest fall was 8% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 8.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Adaptive Biotechnologies Corporation's shareholder treatment is put at 8.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 15% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -27%: lost 27¢ per shareholder dollar. Leverage 57%: owes 57¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Adaptive Biotechnologies Corporation lost about 27 cents for every dollar of shareholders' money, and gross profitability: its products earned about 40 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 57 cents per dollar of assets, and net share issuance: its share count grew 3.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 29% of 102 in its family; net margin -21.5%.
From the record
Adaptive Biotechnologies Corporation's standing among 102 graded names in its industry family: revenue of $277 million in fiscal 2025 ranks in the top 18% by size; a net margin of -21.5% ranks in the top 28%; revenue growth of 14.3% a year over the last 3 filed years ranks in the top 41% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 22% of 110 in its family for leadership; chief executive since 2019.
From the record
Adaptive Biotechnologies Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Robins, Chad M (CEO and Chairman, as filed), filing under that title since 2019-06-26, 7.4 years (top 23% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 7.4 years (top 19%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 22%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 40% of 92 in its family for room to expand.
From the record
Adaptive Biotechnologies Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $70 million against debt of $127 million leaves -10.9% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is -17.7% of revenue (top 22%); a gross margin of 74.2% (top 46%); research spending of 33.9% of revenue (bottom 24%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 42% of 100 in its family for growth drivers.
From the record
Adaptive Biotechnologies Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 14.3% a year over the last three filed years against 28% over all 9, slowing (bottom 39% of its family); the newest year grew 54.8% (top 33%); research spending grew -12.9% a year (bottom 25%); capital spending grew -43.4% a year (bottom 39%) (its annual reports). Adaptive Biotechnologies Corporation reported 2 lines of business in fiscal 2025: Mrd Business at $212 million, Immune Medicine Business at $65 million. 2 of 2 grew in the latest filed year, and the largest line is 77% of revenue (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 30% of 72 in its family for expectations against reality.
From the record
Adaptive Biotechnologies Corporation's newest year against its own record: revenue of $277 million in fiscal 2025 came in 57.5% above the $176 million its prior three years' pace pointed to (top 23% of its family); net income of $59 million against a prior three-year average of $195 million (top 24%); a net margin of -21.5% against losses larger than its revenue before (top 44%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made